Caring at a Cost: Exploring Caregiver Burden and Quality of Life in Terminal Cancer Care

Caring at a Cost: Exploring Caregiver Burden and Quality of Life in Terminal Cancer Care

Caring for a loved one with terminal cancer is a journey filled with challenges. It is also filled with moments that can deeply impact caregivers.

A recent study sought to understand the link between the burden of care and the quality of life among primary caregivers. The findings show a direct correlation between the burden of care and various facets of caregivers’ quality of life. It particularly highlights the negative impacts of caregiver roles and personal strains.

Understanding Caregiver Burden

The study involved 97 primary caregivers of terminal-phase cancer patients. It aimed to show how the burden of care influences various dimensions of caregivers’ quality of life. Using survey questions, researchers focused on the adult carer’s quality of life.

A primary caregiver is someone who takes on the primary responsibility of providing care, support, and assistance to a cancer patient. This person often oversees the well-being, health, and daily needs of the patient. Primary caregivers often provide various forms of support, including physical assistance, emotional support, coordinating medical care, managing medications, assisting with daily activities, and ensuring the overall safety and comfort of the person in their care. The primary caregiver might be a family member, a partner, a friend, or someone who has taken on the responsibility of being the main source of care for the individual in need.

In this study, there was a clear connection between the burden of care and the quality of life among primary caregivers. The personal strains experienced by these caregivers had a direct impact on their quality of life. Factors included their ability to find support, manage stress, and experience personal growth.

While the research specifically focuses on the quality of life among caregivers of cancer patients, these findings extend to diseases like mesothelioma, where caregiving presents similar emotional and practical burdens.

Nurturing Quality of Life in Terminal Cancer Care

This study sheds light on caregivers experiencing the weight of care. It underscores the importance of recognizing these strains. And it shows the direct impact this stress has on other facets of caregivers’ lives.

For social workers and professionals in the helping field, these findings serve as a call to action. Implementing tailored approaches, techniques, and support systems is essential. We need to provide the necessary mental, emotional, social, and familial support to caregivers. There’s an opportunity to enhance the quality of life among primary caregivers of terminal-stage cancer patients.

This study deepens our understanding of caregiver experiences. It also highlights the critical need for comprehensive and targeted support systems to empower those providing care in these challenging circumstances.

Source:

Albert, Wanda Kiyah George, Adi Fahrudin, Steward Lindong, and Husmiati Yusuf. “Self-Control as a Mediator between Caregiver Burden and Quality of Life in Cancer Patient Primary Caregivers.” Islamic Guidance and Counseling Journal 6, no. 2 (October 31, 2023). https://doi.org/10.25217/0020236400600.

 

Similar Posts

  • |

    New Prognostic Factor in Peritoneal Mesothelioma

    Malignant peritoneal mesothelioma is a rare form of mesothelioma that attacks the membrane that lines the abdomen and surrounds internal organs. The outlook for this rare malignancy, which affects fewer than 500 Americans annually, has been improved by the treatment combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination has produced 5-year overall survival rates ranging from 29% to 63%. But not all peritoneal mesothelioma patients are good candidates for CRS/HIPEC. The challenge, for clinicians, is identifying which patients are likely to benefit from the procedure (or even be cured) and which are not. In an effort to help answer that question, French researchers recently tested the prognostic value of the glucose transporter protein GLUT1 as well as…

  • |

    Study Lists Factors That Impact Mesothelioma Prognosis

    Predicting survival in mesothelioma patients does not have to be complicated. A new Parisian study suggests that simple-to-measure factors such as patient age and the histological subtype of the mesothelioma can be highly accurate prognostic indicators. The study followed 170 patients diagnosed with malignant pleural mesothelioma between 2000 and 2010 at Saint Antoine Hospital in Paris. Patients in the study were all treated non-surgically. For each patient, a list of parameters was recorded including age, gender, tobacco use, asbestos exposure, type and duration of symptoms, BMI, C-reactive protein levels and white blood cell and platelet counts.  Inflammation of the pleura (pachypleuritis) was also noted, along with the type of diagnostic surgical procedure, histological subtype, the way in which pleurodesis was performed (for…

  • |

    Predicting Mesothelioma Outcomes with Blood Tests

    Two separate teams of Japanese researchers are delving into the possibilities of blood serum indicators that could help predict outcomes in patients with malignant pleural mesothelioma. Mesothelioma is a rare but aggressive cancer caused by exposure to asbestos. Pleural mesothelioma, a cancer that starts on the lining around the lungs, is the most common form of the disease. It occurs most often in people who have inadvertently inhaled asbestos dust. Mesothelioma is highly resistant to conventional treatments. It is also difficult to predict which patients are likely to do well with standard therapies and which are not, which is referred to as prognosis. But researchers worldwide are continually searching for new ways to diagnose and predict the prognosis of patients with…

  • |

    Drop in Lung Volume Predicts Poor Mesothelioma Outcome

    Decreases in lung volume may be an indicator of treatment response for patients with mesothelioma. Researchers in the U.S. and Australia reached that conclusion after studying the cases of 61 patients with malignant pleural mesothelioma and 216 CT scans taken of them during the course of their standard chemotherapy treatment. Lung volume is a measurement of the amount of air the lung processes (inhales, exhales and holds on to) during the course of a normal breath. People with malignant pleural mesothelioma, a cancer that starts on the lining around the lungs, typically experience a drop in lung volume as the pleural tumor grows and constricts or even invades one of their lungs. The new study measured changes in each mesothelioma patient’s…

  • |

    New Prognostic Tools Could Improve Mesothelioma Treatment

    A pair of cancer researchers from Rome say treatment for malignant pleural mesothelioma could be improved if more clinicians considered the newest prognostic tools in their treatment planning. Pleural mesothelioma is a malignancy of the membranes that encase the lungs. It is caused by exposure to the mineral asbestos and is highly resistant to conventional cancer therapies. Many mesothelioma patients do not survive longer than 12 months from the onset of their symptoms. But Tommaso Mineo, MD, and Vincenzo Ambrogi, PhD, of the Department of Experimental Medicine and Surgery at Policlinico Tor Vergata University say newly discovered biomarkers and other tumor factors could lead to more tailored treatment and, potentially, better outcomes. “Therapy is currently guided by gross tumor characteristics and patient…

  • |

    For Some Patients Chemo Cuts Mesothelioma Survival

    Asbestos disease researchers in Australia say chemotherapy at the end of life may be doing some mesothelioma patients more harm than good. The team from the Asbestos Diseases Research Institute in Rhodes, Australia analyzed the cases of 147 malignant pleural mesothelioma patients who had received compensation from the government’s Dust Diseases Board. The focus of the study was to determine the association between a variety of factors such as age, gender, geographic location, disease stage, histological subtype, length of first-line chemotherapy, and the use of chemotherapy in the last month of their lives. Among the mesothelioma patients studied, most (77%) received more than one treatment modality while 56% received only one. Chemotherapy, which continues to be the most popular first-line treatment…